BlackRock, Inc. 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-17 7:44 pm Purchase | 2025-06-30 | 13G | Aclaris Therapeutics, Inc. ACRS | BlackRock Inc. BLK | 5,471,711 5.100% | 3,439,247 (+169.22%) | Filing |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | Aclaris Therapeutics, Inc. ACRS | BlackRock Inc. BLK | 2,032,464 2.900% | -3,873,408 (-65.59%) | Filing |
| 2024-01-25 4:59 pm Purchase | 2023-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | BlackRock Inc. BLK | 5,905,872 8.300% | 818,437 (+16.09%) | Filing |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | BlackRock Inc. BLK | 5,087,435 7.600% | 1,008,560 (+24.73%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | BlackRock Inc. BLK | 4,078,875 6.700% | 3,031,059 (+289.27%) | Filing |